Literature DB >> 31070681

Evaluating the Association of Clinical Factors With Symptomatic Recurrence of Idiopathic Subglottic Stenosis.

Deanna C Menapace1, Dale C Ekbom1, David P Larson1, Ian J Lalich1, Eric S Edell2, Jan L Kasperbauer1.   

Abstract

Importance: Idiopathic subglottic stenosis (iSGS) is a progressive and potentially life-threatening condition with very few targeted treatment options. Objective: To characterize the clinical factors of patients with iSGS, including body mass index (BMI, calculated as weight in kilograms divided by height in meters squared), and evaluate their association with iSGS symptomatic recurrence. Design, Setting, and Participants: This retrospective medical record review included 186 adult patients with iSGS treated at a single tertiary referral center between January 1, 1989, and December 31, 2015. All data analysis took place from January 1, 2018 to June 30, 2018. Main Outcomes and Measures: The 3 BMI categories were examined for their association with iSGS recurrence. Outcome measurements included time to first symptomatic recurrence (TTFR) and recurrence-free survival (RFS). Comorbidities were recorded.
Results: Of the 186 patients in the study, 182 (98%) were women; mean (interquartile range) patient age, 49 (41-60) years. At iSGS diagnosis, 65 (35%) patients were underweight or normal weight; 45 (24%) were overweight; and 76 (41%) were obese (class 1, 2, or 3). Median BMI was 27.4. Ninety-one patients experienced TTFR at a median of 14 months. Compared with underweight or normal-weight patients, the hazard ratios for the associations of overweight, obese class 1, and obese class 2/3 patients with recurrence were 1.14 (95% CI, 0.65-1.99), 1.74 (95% CI, 1.04-2.93), and 1.04 (95% CI, 0.54-1.99), respectively. No differences in concomitant medical treatment regimens were found. While several comorbidities (gastroesophageal reflux disease, hypertension, hyperlipidemia, and diabetes mellitus) were associated with increasing BMI, they were not associated with iSGS symptomatic recurrence on multivariable analysis. Conclusions and Relevance: Results of this retrospective review show that class 1 obesity was associated with an increased rate of iSGS symptomatic recurrence compared with underweight or normal-weight patients. This association was not seen in class 2 or class 3 obesity. Patients with class 1 obesity should be counseled about this risk to aid in the assessment and management of symptoms.

Entities:  

Mesh:

Year:  2019        PMID: 31070681      PMCID: PMC6512302          DOI: 10.1001/jamaoto.2019.0707

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   6.223


  26 in total

1.  Obesity in menopausal women: more than you might think.

Authors:  Edward Morris; Heather Currie
Journal:  Menopause Int       Date:  2010-09

2.  Subglottic stenosis: a ten-year review of treatment outcomes.

Authors:  Anne F Hseu; Michael S Benninger; Timothy M Haffey; Robert Lorenz
Journal:  Laryngoscope       Date:  2013-10-22       Impact factor: 3.325

3.  Mechanism of association between BMI and dysfunction of the gastro-oesophageal barrier in patients with normal endoscopy.

Authors:  Mohammad H Derakhshan; Elaine V Robertson; Jonathan Fletcher; Gareth-Rhys Jones; Yeong Yeh Lee; Angela A Wirz; Kenneth E L McColl
Journal:  Gut       Date:  2011-08-28       Impact factor: 23.059

4.  Body-mass index and mortality among 1.46 million white adults.

Authors:  Amy Berrington de Gonzalez; Patricia Hartge; James R Cerhan; Alan J Flint; Lindsay Hannan; Robert J MacInnis; Steven C Moore; Geoffrey S Tobias; Hoda Anton-Culver; Laura Beane Freeman; W Lawrence Beeson; Sandra L Clipp; Dallas R English; Aaron R Folsom; D Michal Freedman; Graham Giles; Niclas Hakansson; Katherine D Henderson; Judith Hoffman-Bolton; Jane A Hoppin; Karen L Koenig; I-Min Lee; Martha S Linet; Yikyung Park; Gaia Pocobelli; Arthur Schatzkin; Howard D Sesso; Elisabete Weiderpass; Bradley J Willcox; Alicja Wolk; Anne Zeleniuch-Jacquotte; Walter C Willett; Michael J Thun
Journal:  N Engl J Med       Date:  2010-12-02       Impact factor: 91.245

5.  Association of laryngopharyngeal reflux disease and subglottic stenosis.

Authors:  N C Maronian; H Azadeh; P Waugh; A Hillel
Journal:  Ann Otol Rhinol Laryngol       Date:  2001-07       Impact factor: 1.547

6.  Evidence of extraesophageal reflux in idiopathic subglottic stenosis.

Authors:  Joel H Blumin; Nikki Johnston
Journal:  Laryngoscope       Date:  2011-05-06       Impact factor: 3.325

7.  On the development of idiopathic subglottic stenosis.

Authors:  Edward J Damrose
Journal:  Med Hypotheses       Date:  2008-03-04       Impact factor: 1.538

8.  Gastroesophageal reflux disease as a likely cause of "idiopathic" subglottic stenosis.

Authors:  J R Jindal; M M Milbrath; R Shaker; W J Hogan; R J Toohill
Journal:  Ann Otol Rhinol Laryngol       Date:  1994-03       Impact factor: 1.547

9.  Idiopathic subglottic stenosis: an evolving therapeutic algorithm.

Authors:  Fabien Maldonado; Andrea Loiselle; Zachary S Depew; Eric S Edell; Dale C Ekbom; Michael Malinchoc; Clinton E Hagen; Eran Alon; Jan L Kasperbauer
Journal:  Laryngoscope       Date:  2013-08-08       Impact factor: 3.325

10.  Treatment options in idiopathic subglottic stenosis: protocol for a prospective international multicentre pragmatic trial.

Authors:  Alexander Gelbard; Yu Shyr; Lynne Berry; Alexander T Hillel; Dale C Ekbom; Eric S Edell; Jan L Kasperbauer; David G Lott; Donald T Donovan; C Gaelyn Garrett; Guri Sandhu; James J Daniero; James L Netterville; Josh S Schindler; Marshall E Smith; Paul C Bryson; Robert R Lorenz; David O Francis
Journal:  BMJ Open       Date:  2018-04-10       Impact factor: 2.692

View more
  1 in total

1.  Impact of Adjuvant Medical Therapies on Surgical Outcomes in Idiopathic Subglottic Stenosis.

Authors:  Matthew R Hoffman; Ankita Patro; Li-Ching Huang; Sheau-Chiann Chen; Lynn D Berry; Alexander Gelbard; David O Francis
Journal:  Laryngoscope       Date:  2021-06-12       Impact factor: 3.325

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.